Department of Radiotherapy, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):119-26. doi: 10.1016/j.ijrobp.2009.07.010. Epub 2009 Dec 11.
To determine whether cone-beam CT (CBCT) is effective in monitoring seroma reduction during breast irradiation when compared with conventional CT.
This study included 19 women with Stage T1-2 breast cancer treated with breast-conserving therapy. Each patient underwent two to four CT and multiple CBCT scans (mean, 8; range, 7-13 scans) at various time intervals during radiotherapy. Seroma were contoured by two observers on all scans and checked by one radiation oncologist. Seroma clarity was determined according to The British Columbia Cancer Agency Seroma Clarity Score scale, and conformity index (CI) of the two observers was evaluated. Correlations in seroma contours and seroma characteristics between CBCT and CT, as well as interobserver variation, were examined.
The mean differences in seroma volume between CT and CBCT (3%, p = 0.3) and between the two observers (6%, p = 0.2) were not statistically significant. Seroma clarity correlated significantly with CI for both CT and CBCT (p = 0.02 and p = 0.001, respectively), indicating the higher the seroma clarity score, the greater the CI between the observers. With seroma clarity 3 or higher for CT and CBCT, a high level of observer concordance was shown (all CI of these scans were >or=50%).
Volume discrepancy between CBCT and CT and between the two observers was not statistically significant. Seroma clarity influenced observers' ability to contour on CT or CBCT equally. Therefore, CBCT is a good clinical surrogate for CT in monitoring seroma reduction during breast radiotherapy, especially for patients with seroma clarity score 3 or higher.
与常规 CT 相比,评估锥形束 CT(CBCT)在监测乳腺癌放疗期间血清肿减少方面是否有效。
本研究纳入了 19 名接受保乳治疗的 T1-2 期乳腺癌女性患者。每位患者在放疗期间的不同时间点接受了 2 至 4 次 CT 和多次 CBCT 扫描(平均 8 次;范围 7-13 次)。两位观察者在所有扫描上勾画血清肿轮廓,并由一位放射肿瘤学家检查。根据不列颠哥伦比亚癌症机构血清肿清晰度评分量表评估血清肿清晰度,并评估两位观察者的一致性指数(CI)。评估了 CBCT 和 CT 之间血清肿轮廓和特征的相关性,以及观察者之间的变异。
CT 和 CBCT (3%,p=0.3)以及两位观察者之间(6%,p=0.2)的血清肿体积差异无统计学意义。血清肿清晰度与 CT 和 CBCT 的 CI 显著相关(p=0.02 和 p=0.001),表明血清肿清晰度评分越高,观察者之间的 CI 越大。对于 CT 和 CBCT,血清肿清晰度为 3 或更高时,观察者之间具有高度一致性(这些扫描的所有 CI 均≥50%)。
CBCT 与 CT 以及两位观察者之间的体积差异无统计学意义。血清肿清晰度同样影响观察者在 CT 或 CBCT 上勾画的能力。因此,CBCT 是监测乳腺癌放疗期间血清肿减少的一种良好的临床替代方法,尤其是对于血清肿清晰度评分为 3 或更高的患者。